It was recently announced that the second most utilised soft-tissue surgical robot in the world – Versius has now been used to perform over 30,000 surgical cases globally. The system has been used across a broad range of specialties including urology, general surgery, gynaecology and thoracic surgery. Peer reviewed papers have reported clinical evidence on the safe use of Versius in thoracic, general surgery, urology, gynaecology and TORS in leading international journals including International Journal of Surgery, the Annals of Surgery and BJU International, among others. Due to the adaptability of Versius, 70% of hospitals that use the system are using it across two or more specialties.
CMR Surgical, the Company behind the Versius system has also commenced the world’s first multicentre prospective clinical trial on the use of Versius in paediatric surgery as part of its plans to expand the use of Versius to benefit more patients. The prospective clinical trial is being led by Mr Ewan Brownlee, Consultant Paediatric Urologist at the Southampton Children’s Hospital, part of the University Hospital Southampton NHS Foundation Trust and will assess the safety and efficacy of Versius, for use in urological procedures in paediatric surgery. The clinical trial is taking place over 3 clinical sites in the UK: Southampton Children’s Hospital, the Evelina London Children’s Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust, and Royal Manchester Children’s Hospital part of Manchester University NHS Foundation Trust. Versius is also currently being used in a prospective clinical trial in Transoral Robotic surgery (TORS) in Liverpool University Hospitals NHS Foundation Trust, led by Mr Jason Fleming, after an initial early phase study at Guy’s and St Thomas’ NHS Foundation Trust.
Versius received FDA marketing authorization with an initial indication for adults undergoing cholecystectomy in October 2024 and will continue global expansion, with current use across 29 different countries.
You can read more here:
